A 2-year multicentre, open-label, randomized, controlled study of growth hormone (Genotropin®) treatment in very young children born small for gestational age: Early Growth and Neurodevelopment (EGN) Study.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

However, younger age at treatment initiation is a predictor of favourable response.

To assess the effect of GH treatment on early growth and cognitive functioning in very young (<30 months), short-stature children born SGA.

Who Took Part

PubMed indexes the participants as infants and young children, both men and women.

Children aged 19-29 months diagnosed as SGA at birth, and for whom sufficient early growth data were available, were eligible.

How the Study Was Run

The design is described as randomized and multicenter.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

More than one site took part, so the participants came from several places.

What Was Measured

The subject headings attached to it are Adenoids, Body Height, Child Development, Human Growth Hormone, Hypertrophy, Infant, Small for Gestational Age and Psychomotor Performance.

What This Means in Plain Language

The paper is a randomized and multicenter study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2016 (Clinical endocrinology), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.